Thermo Fisher Scientific Inc. (NYSE:TMO) Receives $624.64 Consensus PT from Analysts

Thermo Fisher Scientific Inc. (NYSE:TMO) has earned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $624.6364.

Several equities research analysts have commented on TMO shares. Barclays raised their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Jefferies Financial Group restated a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Citigroup cut shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research note on Wednesday, September 9th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective on the stock. Finally, Wells Fargo & Company lowered Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research note on Wednesday, September 9th.

Thermo Fisher Scientific Price Performance

TMO opened at $665.77 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company’s 50-day moving average price is $600.50 and its 200 day moving average price is $526.15. Thermo Fisher Scientific has a fifty-two week low of $435.27 and a fifty-two week high of $671.47. The firm has a market cap of $246.17 billion, a price-to-earnings ratio of 35.81, a price-to-earnings-growth ratio of 2.75 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the company earned $4.28 earnings per share. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc Casper sold 275 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 over the last 90 days. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Thermo Fisher Scientific during the second quarter valued at $15,501,867,000. State Street Corp grew its holdings in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after acquiring an additional 229,630 shares in the last quarter. Corient Private Wealth LP acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth $382,547,000. Capital World Investors boosted its position in Thermo Fisher Scientific by 7.0% during the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after purchasing an additional 718,669 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Thermo Fisher Scientific by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock valued at $4,728,129,000 after purchasing an additional 26,425 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher is identified as a key participant in the gene-transfer technologies market, which is projected to expand through 2036 as gene and cell therapies, genomic medicine investment, and vector-engineering technologies advance. This supports potential long-term demand for the company’s instruments, reagents, and manufacturing solutions. Gene Transfer Technologies Market report
• Positive Sentiment: The global bioreactors market is forecast to grow substantially through 2035, driven by single-use systems, automation, and advanced therapies. Thermo Fisher’s inclusion among the leading companies reinforces its exposure to expanding biomanufacturing demand. Bioreactors Market Outlook report
• Positive Sentiment: Thermo Fisher is participating in Precure LLC’s Mayo Clinic-led initiative to generate a one-million-sample multi-omic biomedical dataset. The project could increase visibility for Thermo Fisher’s sequencing, analysis, and research technologies while supporting future AI-driven precision medicine. Precure multi-omic dataset announcement
• Neutral Sentiment: Additional market reports highlight growth opportunities in ADME-toxicology testing, high-content screening, drug-discovery informatics, and automated closed cell-therapy processing—markets in which Thermo Fisher competes. These reports are industry outlooks rather than new contracts or financial guidance. ADME-Toxicology Testing report High Content Screening report Drug Discovery Informatics report
• Negative Sentiment: A market update indicated that TMO was lower ahead of the latest session, suggesting some near-term profit-taking or market caution after its strong recent advance. The report did not identify a new negative company development. Thermo Fisher premarket update

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.